Related Experiment Video
Updated: Feb 6, 2026

Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
Published on: March 1, 2019
Long noncoding RNAs: A new player in the prevention and treatment of diabetic cardiomyopathy?
Chao Ma1,2,3, Huan Luo4, Bing Liu1
1Department of Cardiovascular Surgery, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Insights
Diabetic cardiomyopathy (DCM) involves heart muscle damage due to metabolic issues. This review explores long noncoding RNAs (lncRNAs) in DCM, offering potential new treatment strategies.
Area of Science:
- Cardiology
- Molecular Biology
- Genetics
Background:
- Diabetic cardiomyopathy (DCM) leads to heart muscle necrosis, dysfunction, and potentially heart failure or sudden death.
- Long noncoding RNAs (lncRNAs) are key regulators in biological processes and cardiac disease development.
- The role of lncRNAs in DCM remains largely unexplored.
Purpose of the Study:
- To review current literature on lncRNAs in diabetic cardiomyopathy.
- To identify potential therapeutic targets and strategies for DCM prevention and treatment.
Main Methods:
- Literature review of studies investigating lncRNAs in diabetic cardiomyopathy.
- Analysis of the roles of specific lncRNAs in DCM pathogenesis.
Main Results:
- lncRNAs are increasingly recognized for their involvement in cardiac diseases.
- Specific lncRNAs may serve as biomarkers or therapeutic targets for DCM.
Conclusions:
- lncRNAs represent a promising area for understanding and treating diabetic cardiomyopathy.
- Further research into lncRNA functions in DCM could lead to novel clinical interventions.
Abstract:
Diabetic cardiomyopathy (DCM) can cause extensive necrosis of the heart muscle by metabolic disorders and microangiopathy, with subclinical cardiac dysfunction, and eventually progress to heart failure, arrhythmia, and cardiogenic shock; severe patients may even die suddenly. Long noncoding RNAs (lncRNAs) are a class of nonprotein-coding RNAs longer than 200 nucleotides. They have critical roles in various biological processes, including gene expression regulation, genomic imprinting, nuclear-cytoplasmic trafficking, RNA splicing, and translational control. Recent studies indicated that lncRNAs extensively participate in the development of diverse cardiac diseases, such as cardiac ischaemia, hypertrophy, and heart failure. Little is known about lncRNA in DCM. In this review, we summarize the current literature on lncRNAs in DCM studies, aiming to provide new methods for DCM's future prevention and treatment strategies.
Related Concept Videos
lncRNA - Long Non-coding RNAs
Cardiomyopathy II: Dilated Cardiomyopathy
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
piRNA - Piwi-interacting RNAs

